To investigate the therapeutic potency of Mebendazole in combination with standard treatment, mesalamine, in Ulcerative colitis patients

Mashhad University of Medical Sciences0 个研究点目标入组 54 人开始时间: 待定最近更新: 2022年5月2日

试验速览

暂无简介。

•Provide written documentation of informed consent to participate in the study.
•Male or female aged 18 to 60 years.
•Subjects with a confirmed diagnosis of moderate proctosigmoiditis and Left-sided colitis. Diagnosis established by endoscopy and histology.
•Participants have no proven current active gastrointestinal infection.

•Subjects with Crohn's disease or other types of colitis including Infectious, Radiation or Ischemic colitis.
•Allergy to Mesalamine or Mebendazole.
•Subjects who have a positive pregnancy test, or breast feeding.
•Subjects treated with immuno-modulatory drugs from two months before screening or receiving pro- or antibiotics from two weeks from screening.
•Patients who have already received metronidazole or Mebendazole for parasitic worm infection.
•Subjects with leukopenia, thrombocytopenia, neutropenia, Hb< 10
•Subjects with Chronic Medical Conditions including heart diseases, lung diseases esp. Tuberculosis, Renal dysfunction, liver diseases, coagulation disorders, Drug abuse
•Patients with Ulcerative Proctitis.

发起方